Cybin Inc. (CYBN)
USD 6.5
(-1.81%)
USD 6.5
(-1.81%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -424 Thousand CAD | -68.92% |
| 2022 | -251 Thousand CAD | -49.4% |
| 2021 | -168 Thousand CAD | -184.0% |
| 2020 | 200 Thousand CAD | 0.0% |
| 2019 | - CAD | 0.0% |
| 2018 | - CAD | 0.0% |
| 2016 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -138 Thousand CAD | 2.82% |
| 2023 Q3 | -142 Thousand CAD | -100.0% |
| 2023 FY | -424 Thousand CAD | -68.92% |
| 2023 Q4 | -142 Thousand CAD | 0.0% |
| 2023 Q2 | -71 Thousand CAD | -2.9% |
| 2023 Q1 | -69 Thousand CAD | -1.47% |
| 2022 Q4 | -68 Thousand CAD | 4.23% |
| 2022 Q3 | -71 Thousand CAD | -20.34% |
| 2022 Q1 | -53 Thousand CAD | -20.45% |
| 2022 Q2 | -59 Thousand CAD | -11.32% |
| 2022 FY | -251 Thousand CAD | -49.4% |
| 2021 Q2 | -42 Thousand CAD | -10.53% |
| 2021 Q3 | -44.00 CAD | 99.9% |
| 2021 Q1 | -38 Thousand CAD | -5755.16% |
| 2021 FY | -168 Thousand CAD | -184.0% |
| 2021 Q4 | -44 Thousand CAD | -99900.0% |
| 2020 FY | 200 Thousand CAD | 0.0% |
| 2020 Q3 | - CAD | 0.0% |
| 2020 Q4 | -649.00 CAD | 0.0% |
| 2020 Q2 | - CAD | -100.0% |
| 2020 Q1 | 200 Thousand CAD | 0.0% |
| 2019 Q3 | - CAD | 0.0% |
| 2019 FY | - CAD | 0.0% |
| 2018 FY | - CAD | 0.0% |
| 2016 FY | - CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 160 Thousand USD | 365.0% |
| Armata Pharmaceuticals, Inc. | -29.24 Million USD | 98.55% |
| Actinium Pharmaceuticals, Inc. | -709 Thousand USD | 40.197% |
| Azitra, Inc. | 260.45 Thousand USD | 262.795% |
| Can-Fite BioPharma Ltd. | 743 Thousand USD | 157.066% |
| Chromocell Therapeutics Corporation | -2.57 Million USD | 83.562% |
| Calidi Biotherapeutics, Inc. | -1.25 Million USD | 66.242% |
| CEL-SCI Corporation | -3.95 Million USD | 89.288% |
| iBio, Inc. | -1.02 Million USD | 58.634% |
| Lineage Cell Therapeutics, Inc. | 8.27 Million USD | 105.124% |
| MAIA Biotechnology, Inc. | - USD | Infinity% |
| Matinas BioPharma Holdings, Inc. | -13.39 Million USD | 96.834% |
| NovaBay Pharmaceuticals, Inc. | 7.89 Million USD | 105.37% |
| NanoViricides, Inc. | -759.01 Thousand USD | 44.138% |
| Oragenics, Inc. | -15.45 Million USD | 97.256% |
| BiomX Inc. | -1.22 Million USD | 65.472% |
| BiomX Inc. | -1.22 Million USD | 65.472% |
| Protalix BioTherapeutics, Inc. | 42.51 Million USD | 100.997% |
| Palatin Technologies, Inc. | 4.39 Million USD | 109.653% |
| Scorpius Holdings, Inc. | -2.21 Million USD | 80.87% |
| Theriva Biologics, Inc. | -135 Thousand USD | -214.074% |